CytoMed Therapeutics Rejects Misleading Claims, Confirms Ongoing Clinical Trial Progress
GDTC is trading near its 52-week low of $0.728 (7.3% above the low).
Summary
CytoMed Therapeutics issued a statement refuting inaccurate claims about its research programs and operations, reaffirming its lead CAR γδ T cell program is in an ongoing first-in-human clinical trial with regulatory approval.
Key Events · Product Development and Regulatory · GDTC
-
Refutes Misleading Claims
The company issued a statement to address and categorically reject inaccurate and misleading claims circulating publicly regarding its research programs, clinical progress, and operations.
-
Reaffirms Clinical Trial Progress
CytoMed confirmed its lead CAR γδ T cell program has received regulatory approval for an ongoing first-in-human clinical trial at National University Hospital, Singapore.
-
Emphasizes Compliance and Transparency
The company reaffirmed its commitment to regulatory compliance, scientific rigor, and transparent disclosure, reserving the right to take action against false information.
Analysis · GDTC · Life Sciences
This filing is important as CytoMed Therapeutics, a clinical-stage biopharmaceutical company, is actively addressing and refuting potentially damaging inaccurate claims about its core operations and clinical development. For a company of its size and stage, maintaining investor confidence and a clear narrative around its clinical progress and regulatory compliance is crucial. The reaffirmation of its lead CAR γδ T cell program's ongoing first-in-human clinical trial, which received regulatory approval, provides clarity and counters any misinformation that might suggest otherwise. This proactive communication aims to protect its reputation and stakeholder interests, especially following a recent positive update on clinical progress and funding on January 13.
How filings like this one have moved
In the 30 days to Sep 18, 2026, 29.1% of the 1692 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GDTC was trading at $0.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.2M. The 52-week trading range was $0.73 to $3.68. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.